IDH1 and neoplasm: IDH mutation acquisition is a relevant event in many tumor progressions, and targeting IDH mutations at an early stage of the disease can be crucial to halt disease progression and prevent the acquisition of additional genetic alterations that could reduce the effectiveness of IDH inhibitors.